Colon Cancer News and Research

Latest Colon Cancer News and Research

Bionomics files key U.S. patents relating to cancer drug target BNO69

Bionomics Limited announced today that it has filed further patent applications in key markets (including the US) relating to its proprietary cancer drug target BNO69.

9 May 2005

After surgery check colon tumors for signs of syndrome, study suggests

A new study suggests that, after surgery, all colon tumors should be tested to learn if the patient may have an inherited syndrome that carries an extremely high risk of cancer. It also suggests that this prescreening can be done using a relatively inexpensive microscopy test already used in hospital pathology laboratories.

5 May 2005

Critical lock and key mechanism found for the assembly of tumor blood vessels

A critical lock and key mechanism that allows the final step in the completion of new blood vessel formation has been identified by a University of California, San Diego (UCSD) School of Medicine team in research that promises to lead to a new way to halt tumor growth by cutting off the tumor blood supply.

3 May 2005

Gene variant that increases colon cancer risk

A paper published in this week's Journal of Clinical Oncology says Transforming Growth Factor Beta Receptor 1*6A (TGFBR1*6A) - a mutated gene present in nearly one in eight people and the most commonly inherited cancer susceptibility gene identified so far - might be responsible for a significant proportion of familial colorectal cancers.

2 May 2005

Hereditary colorectal cancer risk lowered in those without certain gene defect

Families with a certain type of hereditary colorectal cancer have a reduced cancer risk if they do not have a gene defect found in many with this type of cancer risk, according to a study in the April 27 issue of JAMA.

26 Apr 2005

“Virtual Colonoscopy” effective in finding most polyps but may miss small ones

A type of noninvasive “virtual colonoscopy” can diagnose medium to large polyps as well as traditional colorectal probes can, but it may miss some smaller yet potentially cancerous growths, according to a new review of studies.

21 Apr 2005

Researchers find promising cancer-fighting power of synthetic cell-signaling molecule

Novel anti-cancer compounds called Enigmols suppress the growth of human cell lines representing cancers of the prostate, breast, colon, ovary, pancreas, brain and blood, and reduce tumors in three animal studies, new research shows.

19 Apr 2005

Researchers determine structure of binding site of colon-cancer drug Erbitux and its protein target

Researchers at the University of Pennsylvania School of Medicine have determined the precise molecular details of how Erbitux, a recently approved colorectal cancer drug, binds to its target on cancer cells. Knowing this chemical configuration will lead to better drug design for this family of cancer medications.

19 Apr 2005

Can cancer be prevented?

Common habits – what we eat, how much we exercise, smoke and use alcohol – contribute to about a third of cancer deaths, according to the American Cancer Society.

12 Apr 2005

Chemoembolization, first-line treatment for liver cancer

New research by Jeff Geschwind, M.D., director of interventional radiology and associate professor at Johns Hopkins University School of Medicine, has shown that liver cancer patients, most of whom have inoperable tumours, could benefit from chemoembolization, a nonsurgical treatment option that delivers a high-dose of chemotherapy to the tumour while decreasing blood flow through the arteries feeding the tumour, known as embolization.

4 Apr 2005

Exposure to organochlorine compounds increases the risk of suffering colorectal cancer

A team of researchers at the Universitat Autònoma de Barcelona, The Catalan Institute of Oncology and the Higher Council for Scientific Research (CSIC) have published a study indicating that exposure to organochlorine compounds, which we ingest in our diets, increases the risk of suffering colorectal cancer.

3 Apr 2005

New prostate cancer test

Tessera, Inc., a Seattle-based biomedical company, has released its first product, ProstaMark EPCA (Early Prostate Cancer Antigen), as an Analyte Specific Reagent (ASR) for commercial use in pathology laboratories to assist pathologists in their efforts to determine if cancer is present in the prostate.

28 Mar 2005

Primary care office strategies may increase colon cancer screening

Patients are more likely to receive colorectal cancer screening when primary care practices use an office systems approach, according to an article in the March 28 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

28 Mar 2005

Strawberries destroy cancer cells

Researchers specializing in the health benefits of plant compounds have shown that quercetin, a phytonutrient found in abundance in strawberries and other fruits, can induce programmed self-destruction of human cancer cells.

23 Mar 2005

Conference to assess evidence on management of menopause-related symptoms

The National Institutes of Health (NIH) will hold a State-of-the-Science Conference on Management of Menopause-Related Symptoms, March 21-23, 2005, at the Natcher Conference Center on the NIH campus in Bethesda, Maryland.

16 Mar 2005

Prostate screenings could be used to encourage colon checks

Colon cancer is the third leading cause of cancer death in men, but according to a new University of Michigan Health System study, fewer than half of men surveyed were up-to-date with colon cancer screenings.

3 Mar 2005

Important advance in our understanding of colorectal cancer

An international team of medical scientists has made an important advance in our understanding of the second most fatal form of cancer in the industrialized world. Professor Jeremy R. Jass, who holds a Canada Research Chair in Gastrointestinal Pathology at McGill University in Montreal

3 Mar 2005

Important player in the development of colon cancer

Cancer growth is a long, complex, multi-stage process involving a variety of different "players." This complexity is part of the difficulty facing cancer researchers. Meanwhile, each discovery or identification of a new "player," or previously unknown stage in the process, offers new opportunities for blocking the disease.

3 Mar 2005